基于MRI与临床数据评估RAPNO标准在髓母细胞瘤及其他软脑膜播散肿瘤中的应用
该多中心回顾性队列纳入269例髓母细胞瘤、高级别胶质瘤、胚胎性肿瘤、生殖细胞肿瘤或脉络丛乳头状瘤患者,评估RAPNO标准的观察者间一致性、客观缓解率及无进展生存期。RAPNO判断客观缓解的观察者间一致率为83.8%(k=0.815,P<0.001),客观缓解率0.565(95%CI 0.505-0.625),客观缓解状态与无进展生存期均与总生存期相关。
要点
- RAPNO标准判断客观缓解的观察者间一致率为83.8%(k=0.815,P<0.001)。
- 全组RAPNO客观缓解率为0.565(95%CI 0.505-0.625),中位随访4.0年。
- 1年界标分析中客观缓解HR=0.079、无进展生存期HR=10.192,均与总生存期相关(P<0.001)。
核心结论
- RAPNO标准在髓母细胞瘤及其他软脑膜播散肿瘤的治疗反应评估中表现出一致性良好,其判定的客观缓解与无进展生存期均与总生存期相关。
研究设计与样本
- 多中心回顾性队列,纳入269例髓母细胞瘤、高级别胶质瘤、胚胎性肿瘤、生殖细胞肿瘤或脉络丛乳头状瘤患者,分析MRI与临床数据。
主要发现
- 全组中位随访时间4.0年,RAPNO判定的客观缓解率为0.565(95%CI 0.505-0.625)。
- 两名评估者(神经放射科医生与神经肿瘤科医生)判断客观缓解的观察者间一致率为83.8%(k=0.815,P<0.001)。
- 在0.5年、1.0年、1.5年界标分析中,RAPNO判定的客观缓解状态与无进展生存期均预测总生存期(1年界标:客观缓解HR=0.079,P<0.001;无进展生存期HR=10.192,P<0.001)。
- 亚组分析中,客观缓解状态与无进展生存期对所有肿瘤亚型及治疗方式均预测总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group has made recommendations for response assessment in patients with medulloblastoma (MBL) and leptomeningeal seeding tumors, these criteria have yet to be evaluated. METHODS: We examined MR imaging and clinical data in a multicenter retrospective cohort of 269 patients with MBL diagnoses, high grade glioma, embryonal tumor, germ cell tumor, or choroid plexus papilloma. Interobserver agreement, objective response (OR) rates, and progression-free survival (PFS) were calculated. Landmark analyses were performed for OR and progression status at 0.5, 1.0, and 1.5 years after treatment initiation. Cox proportional hazards models were used to determine the associations between OR and progression with overall survival (OS). Subgroup analyses based on tumor subgroup and treatment modality were performed. RESULTS: The median follow-up time was 4.0 years. In all patients, the OR rate was .0.565 (95% CI: 0.505-0.625) by RAPNO. The interobserver agreement of OR determination between 2 raters (a neuroradiologist and a neuro-oncologist) for the RAPNO criteria in all patients was 83.8% (k statistic = 0.815; P < 0.001). At 0.5-, 1.0-, and 1.5-year landmarks, both OR status and PFS determined by RAPNO were predictive of OS (hazard ratios [HRs] for 1-year landmark: OR HR = 0.079, P < 0.001; PFS HR = 10.192, P < 0.001). In subgroup analysis, OR status and PFS were predictive of OS for all tumor subtypes and treatment modalities. CONCLUSION: RAPNO criteria showed excellent consistency in the treatment response evaluation of MBL and other leptomeningeal seeding tumors. OR and PFS determined by RAPNO criteria correlated with OS.
引用
- Peng J, Zhou H, Tang O, et al. Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data. Neuro Oncol. 2020. PMID: 32215549. doi:10.1093/neuonc/noaa072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。